AU2013270979B2 - Imidazo-oxadiazole and imidazo-thiadiazole derivatives - Google Patents

Imidazo-oxadiazole and imidazo-thiadiazole derivatives Download PDF

Info

Publication number
AU2013270979B2
AU2013270979B2 AU2013270979A AU2013270979A AU2013270979B2 AU 2013270979 B2 AU2013270979 B2 AU 2013270979B2 AU 2013270979 A AU2013270979 A AU 2013270979A AU 2013270979 A AU2013270979 A AU 2013270979A AU 2013270979 B2 AU2013270979 B2 AU 2013270979B2
Authority
AU
Australia
Prior art keywords
mmol
formula
compound
added
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013270979A
Other languages
English (en)
Other versions
AU2013270979A1 (en
Inventor
Anna Quattropani
Dominique Swinnen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of AU2013270979A1 publication Critical patent/AU2013270979A1/en
Application granted granted Critical
Publication of AU2013270979B2 publication Critical patent/AU2013270979B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013270979A 2012-06-05 2013-05-23 Imidazo-oxadiazole and imidazo-thiadiazole derivatives Active AU2013270979B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261655544P 2012-06-05 2012-06-05
EP12170840.8A EP2671885A1 (en) 2012-06-05 2012-06-05 Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
EP12170840.8 2012-06-05
US61/655,544 2012-06-05
PCT/EP2013/001521 WO2013182274A1 (en) 2012-06-05 2013-05-23 Imidazo-oxadiazole and imidazo-thiadiazole derivatives

Publications (2)

Publication Number Publication Date
AU2013270979A1 AU2013270979A1 (en) 2015-01-22
AU2013270979B2 true AU2013270979B2 (en) 2017-04-27

Family

ID=46320789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013270979A Active AU2013270979B2 (en) 2012-06-05 2013-05-23 Imidazo-oxadiazole and imidazo-thiadiazole derivatives

Country Status (9)

Country Link
US (2) US9932354B2 (enExample)
EP (2) EP2671885A1 (enExample)
JP (1) JP6167465B2 (enExample)
CN (1) CN104395324B (enExample)
AU (1) AU2013270979B2 (enExample)
CA (1) CA2875628C (enExample)
ES (1) ES2582556T3 (enExample)
IL (1) IL236076B (enExample)
WO (1) WO2013182274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
CA3072362A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
MY209034A (en) 2018-10-05 2025-06-17 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509477A (ja) * 1993-04-26 1996-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ 慢性神経変性疾患でのサベルゾールの使用
DE60230160D1 (de) * 2001-02-20 2009-01-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
US6825190B2 (en) * 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
PT1532145E (pt) * 2002-08-02 2007-01-31 Vertex Pharma Composiçoes de pirazole úteis como inibidores de gsk-3
ES2397275T3 (es) * 2005-08-04 2013-03-05 Sirtris Pharmaceuticals, Inc. Derivados de imidazopiridina como agentes moduladores de la sirtuína
CN101878219B (zh) * 2007-09-27 2014-04-02 西班牙国家癌症研究中心 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
CA2732186A1 (en) * 2008-07-29 2010-02-04 Merck Patent Gmbh Imidazothiadiazole derivatives
RU2518892C2 (ru) * 2008-09-23 2014-06-10 Виста Лабораториз Лтд. Лиганды для агрегированных молекул тау-белка

Also Published As

Publication number Publication date
US20150175628A1 (en) 2015-06-25
CA2875628A1 (en) 2013-12-12
ES2582556T3 (es) 2016-09-13
JP6167465B2 (ja) 2017-07-26
US9932354B2 (en) 2018-04-03
AU2013270979A1 (en) 2015-01-22
IL236076A0 (en) 2015-02-01
EP2855488A1 (en) 2015-04-08
IL236076B (en) 2019-05-30
US20180215770A1 (en) 2018-08-02
WO2013182274A1 (en) 2013-12-12
CN104395324B (zh) 2017-09-12
EP2671885A1 (en) 2013-12-11
CA2875628C (en) 2021-01-19
EP2855488B1 (en) 2016-04-13
US10696690B2 (en) 2020-06-30
JP2015522556A (ja) 2015-08-06
CN104395324A (zh) 2015-03-04

Similar Documents

Publication Publication Date Title
AU2014214254B2 (en) Macrocyclic Pyridazinone derivatives
RU2610840C2 (ru) Тиазолопиримидины
KR20080087070A (ko) 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
AU2013292782B2 (en) Fused triazole derivatives as gamma secretase modulators
US8741923B2 (en) Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
AU2013269996B2 (en) Spiro tetrahydro - benzothiophen derivatives useful for the treatment neurodegenerative diseases
US10696690B2 (en) Imidazo-oxadiazole and imidazo-thiadiazole derivatives
IL302837A (en) Aryl derivatives for treating trpm3 mediated disorders
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
EP2307426A1 (en) Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
JP7734147B2 (ja) Ｓｓｔｒ４アゴニストとしてのｎ－（ヘテロシクリル及びヘテロシクリルアルキル）－３－ベンジルピリジン－２－アミン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)